CRISPR Therapeutics AG (CRSP) Share-based Compensation (2015 - 2026)

CRISPR Therapeutics AG has reported Share-based Compensation for 12 years, with the latest figure at $72.3 million in Q1 2026.

• Quarterly Share-based Compensation rose 257.71% year-over-year to $72.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72.3 million (down 17.25% YoY) and the FY2025 annual result came in at $72.5 million, down 16.25% from the prior year.
• Share-based Compensation climbed to $72.3 million in Q1 2026 per CRSP's latest filing, from $18.1 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $72.3 million in Q1 2026 and troughed at $17.6 million in Q2 2025.
• A 5-year average of $26.7 million and a median of $21.8 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2025 and 2026: Share-based Compensation decreased 25.62% in 2025, then surged 257.71% in 2026.
• Over 5 years, Share-based Compensation stood at $22.8 million in 2022, then slipped by 19.35% to $18.4 million in 2023, then grew by 19.33% to $21.9 million in 2024, then declined by 17.63% to $18.1 million in 2025, then surged by 299.96% to $72.3 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $72.3 million, $18.1 million, and $60.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.